Description

S4 Andarine + Cardarine Formula – Product Information

This formula brings together the potential benefits of two distinct compounds, each with its unique mechanism of action, to support research objectives. S4 Andarine’s anabolic properties, combined with the potential improvements in endurance from Cardarine, may contribute to increased muscle mass and strength in research subjects.

Cardarine’s potential effects on endurance, fat oxidation, and energy expenditure may enhance stamina, leading to longer and more intense energy expenditure. This combination may also support increased fat loss and improvements in body composition in research subjects.
It’s important to note that the specific interactions and effects of this combined formula may vary, and further research is needed to fully understand their combined effects when used in research studies.

• This formula consists of S4 Andarine and Cardarine.
• S4 Andarine + Cardarine Combined formula capsules consist of 30mg S4 Andarine and 10mg Cardarine, totaling 40mg per capsule for a total of 2400mg.

S4 Andarine

A scientific study published in 2005 examined the effects of Andarine S-4 in the skeletal muscles, bones, and pituitary glands of castrated male rats. A treatment protocol (3 and 10mg/kg S4- Andarine for 8 weeks) was commenced 12 weeks after castration. Andarine (doses 3 and 10 mg/kg) restored soleus muscle mass and strength, and levator ani muscle mass to that seen prior to castration, or in intact animals.

This makes S4 an investigational Selective androgen receptor modulator, for possible treatment of conditions related to muscle wasting, osteoporosis, and benign prostatic hyperplasia (BPH). It has the ability to mimic many of the beneficial pharmacologic effects associated with testosterone.

Cardarine

GW-501516, also known as Cardarine, is a PPAR agonist. Cardarine is used in research for its potential to facilitate fat-burning by increasing endurance and stamina. A study done on the effects of GW-501516 for enhancing running endurance in Kunming mice demonstrated that a 3-week dosing protocol with GW501516 was able to increase performance, related to running of both trained and untrained mice. Similar to training, GW501516 showed an increase in mitochondrial fatty acid oxidation and enhanced fat metabolism in muscle tissue. This could potentially lead to less demanding cardiovascular work, increasing weekly deficits, and resulting in increased fat loss.